A clinical trial involving patients with stage II to IV COPD revealed that transplantation of autologous p63+ progenitor cells in patients from the intervention group led to an average increase of 18.2% in gas transfer capacity in 24 weeks after transplantation, whereas the control group experienced a 17.4% decline in gas transfer capacity. This evidence concerns the gene TP63 and chronic obstructive pulmonary disease.